NeuroControl Vocare Reduces Urinary Tract Infection By 78%, Receives HDE
This article was originally published in The Gray Sheet
Use of NeuroControl's Vocare bladder control system reduced urinary tract infections after surgery by 78% in 23 patients involved in the firm's ongoing U.S. trial.
You may also be interested in...
FDA approval of Rochester Medical's FemSoft insert for female stress urinary incontinence on Sept. 30, the final day of the federal government's fiscal year, apparently put the agency's total number of approved, original premarket approval applications for the year at 33, down from 42 in 1998 and 46 in 1997.
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.